Trial reportThe American journal of tropical medicine and hygiene2025
Enhancing Primaquine Adherence for Plasmodium vivax Malaria: A Cluster-Randomized Controlled Trial in Myanmar.
Trial report in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The rising prevalence of Plasmodium vivax (P. vivax) malaria challenges elimination efforts, particularly in the Greater Mekong Subregion, although adherence to the required 14-day primaquine (PQ) regimen remains a major obstacle. This study evaluated the effectiveness of a family-administered, directly observed treatment intervention in improving adherence to PQ among patients with confirmed P. vivax from October 2022 to March 2023. A cluster-randomized controlled trial was conducted in five intervention villages and five control villages in Kachin State, Myanmar. A total of 427 patients in the intervention group (supervised dosing) and 425 patients in the control group (unsupervised dosing), all diagnosed with P. vivax, underwent a 14-day PQ regimen, with the intervention group being supervised by trained family members. Pill counts on day 14 were assessed and compared between the two groups using Poisson generalized linear mixed models. Parasite reappearance identified by polymerase chain reaction was compared between the two groups using survival analysis. Cumulative malaria incidence at baseline, as well as at months 6 and 12, was compared between the two groups. Treatment adherence was significantly higher in the intervention group (98.8%) compared with the control group (77.6%). Parasite reappearance rates were similar between the groups (P = 0.20) on days 14, 28, and 42. However, the cumulative incidence of malaria over 1 year was significantly lower in the intervention group (P <0.001) compared with the control group. In malaria-endemic areas with limited resources, a family-administered, directly observed treatment intervention offers an efficient approach to enhance PQ adherence and achieve the radical cure of P. vivax malaria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.